JP2013533227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533227A5 JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- fgf21
- acetylamino
- des181
- conh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 23
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 23
- 102220047964 rs587783194 Human genes 0.000 claims 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- -1 17-carboxyheptadecanoylamino Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/057986 WO2010142665A1 (en) | 2009-06-11 | 2010-06-08 | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| EPPCT/EP2010/057986 | 2010-06-08 | ||
| CN2010001099 | 2010-07-21 | ||
| CN2010/001099 | 2010-07-21 | ||
| US37329010P | 2010-08-13 | 2010-08-13 | |
| US61/373,290 | 2010-08-13 | ||
| PCT/EP2011/059273 WO2011154349A2 (en) | 2010-06-08 | 2011-06-06 | Fgf21 analogues and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533227A JP2013533227A (ja) | 2013-08-22 |
| JP2013533227A5 true JP2013533227A5 (OSRAM) | 2014-07-24 |
Family
ID=49179102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513645A Withdrawn JP2013533227A (ja) | 2010-06-08 | 2011-06-06 | Ｆｇｆ２１類似体および誘導体 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2013533227A (OSRAM) |
| WO (1) | WO2011154349A2 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| TWI513705B (zh) * | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CN104364261B (zh) * | 2012-06-11 | 2017-04-05 | 伊莱利利公司 | 成纤维细胞生长因子21变体 |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| WO2015103782A1 (en) * | 2014-01-13 | 2015-07-16 | Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co | Fgf21 mutant and conjugate thereof |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR102427527B1 (ko) * | 2014-12-23 | 2022-08-01 | 노보 노르디스크 에이/에스 | Fgf21 유도체 및 그것의 용도 |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| US20190142963A1 (en) | 2016-04-15 | 2019-05-16 | Richard D. DiMarchi | Fgf21 c-terminal peptide optimization |
| JP7023518B2 (ja) * | 2016-05-25 | 2022-02-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 分泌障害の処置のための方法および組成物 |
| WO2017220706A1 (en) | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| EP3612637A4 (en) | 2017-04-21 | 2021-01-27 | Yuhan Corporation | DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| US20220016211A1 (en) | 2020-01-08 | 2022-01-20 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| AU2022341345A1 (en) | 2021-09-08 | 2024-03-28 | Leto Laboratories Co., Ltd | Fgf21 mutant protein and use thereof |
| KR20250031229A (ko) | 2022-06-03 | 2025-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 골수 유래된 성장 인자의 재조합 발현 |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| US20250186549A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| ATE444307T1 (de) | 2004-09-02 | 2009-10-15 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| EP2185178B1 (en) * | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| EP2358749B1 (en) * | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| CN102361647B (zh) * | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| WO2010142665A1 (en) * | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
-
2011
- 2011-06-06 WO PCT/EP2011/059273 patent/WO2011154349A2/en not_active Ceased
- 2011-06-06 JP JP2013513645A patent/JP2013533227A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533227A5 (OSRAM) | ||
| JP2018505146A5 (OSRAM) | ||
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| JP2012529463A5 (OSRAM) | ||
| HRP20181026T1 (hr) | Dugodjelujuće formulacije inzulina | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| UA114700C2 (uk) | Тверда фармацевтична форма для перорального застосування та процес її виготовлення | |
| JP2013530974A5 (OSRAM) | ||
| WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| JP2015513544A5 (OSRAM) | ||
| HRP20140480T1 (hr) | Pegilirani spojevi inzulina lispro | |
| CY1117576T1 (el) | Δινουκλεοτιδικα προφαρμακα | |
| EA201100969A1 (ru) | Солевые формы органического соединения | |
| WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
| WO2009043466A3 (en) | Therapeutic use of the peptide gluten exorphin a5 | |
| RU2016135543A (ru) | Новые производные инсулина и их применение в медицине | |
| ATE520406T1 (de) | Kristalline form des ibandronat-natriums | |
| WO2009046822A3 (en) | Use of the peptide ymdgtmsqv as a therapeutic agent | |
| WO2009033712A3 (en) | Use of melanotan ii as a therapeutic agent | |
| JP2017508741A5 (OSRAM) | ||
| JP2011046708A5 (OSRAM) | ||
| WO2009046858A3 (en) | Therapeutic uses of kisspeptin 13 and compositions thereof | |
| WO2009040050A3 (en) | Use of calcitonin as anti-angiogenic agent | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. |